{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:23:58Z","timestamp":1772249038450,"version":"3.50.1"},"reference-count":56,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T00:00:00Z","timestamp":1238025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to investigate the influence of continued injecting drug use, enrolment in an opiate substitution treatment programme (OSTP), or cessation of injecting drug use on the uptake and course of antiretroviral therapy (ART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A prospective observational study of all participants in the Swiss HIV Cohort Study followed between 1997 and 2006 was carried out.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We distinguished four groups of former or current injecting drug users (IDUs): (i) abstinent former IDUs; (ii) persons in OSTPs without concomitant injecting drug use; (iii) persons in OSTPs with concomitant injecting drug use; (vi) current IDUs. These groups were compared with a group of patients who had never been IDUs. Factors related to ART uptake and virological endpoints were analysed using logistic generalized estimating equations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We followed 8660 participants for 48\u2003477 person\u2010years; 29.7% were in the IDU HIV transmission group. The likelihood of being on ART at biannual visits was lower among individuals in OSTPs with concomitant injecting drug use [odds ratio (OR) 0.79; 95% confidence interval (CI) 0.71\u20130.89] and current IDUs (OR 0.80; 95% CI 0.67\u20130.96), compared with those who had never been IDUs (reference), abstinent former IDUs (OR 1.13; 95% CI 1.02\u20131.25) and individuals in OSTPs without injecting drug use (OR 1.18; 95% CI 1.06\u20131.31). The likelihood of suppressed viral replication on ART was similar among those who had never been IDUs, abstinent former IDUs and individuals in an OSTP without injecting drug use, and lower among those in OSTPs with concomitant drug use (OR 0.82; 95% CI 0.72\u20130.93) and current IDUs (OR 0.81; 0.65\u20131.00). Adherence to ART was decreased among persons with continued injecting drug use, and correlated with virological outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Uptake of and virological response to ART were improved among abstinent former IDUs and persons in OSTPs without concomitant injecting drug use, compared with persons with continued injecting drug use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00701.x","type":"journal-article","created":{"date-parts":[[2009,3,27]],"date-time":"2009-03-27T02:51:17Z","timestamp":1238122277000},"page":"407-416","source":"Crossref","is-referenced-by-count":64,"title":["Uptake of and virological response to antiretroviral therapy among HIV\u2010infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study"],"prefix":"10.1111","volume":"10","author":[{"given":"R","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rickenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Furrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Elzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hirschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Ledergerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Swiss HIV Cohort Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"UNAIDS. Joint United Nations Programme on HIV\/AIDS (UNAIDS) and World Health Organization (WHO): AIDS epidemic update 2007. Available athttp:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/EpiUpdate\/EpiUpdArchive\/2007\/accessed 1 March 2009.."},{"key":"e_1_2_6_3_2","first-page":"1733","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs","volume":"372","author":"Mathers BM","year":"2008","journal-title":"a systematic review"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fbd1ed"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200107010-00006"},{"key":"e_1_2_6_6_2","first-page":"151","article-title":"Adherence to HAART in French HIV\u2010infected injecting drug users","volume":"14","author":"Moatti JP","year":"2000","journal-title":"the contribution of buprenorphine drug maintenance treatment. The MANIF 2000 Study Group"},{"key":"e_1_2_6_7_2","first-page":"195","article-title":"Adherence to antiretroviral therapy among HIV\u2010infected methadone patients","volume":"26","author":"Stein MD","year":"2000","journal-title":"effect of ongoing illicit drug use"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200304150-00009"},{"issue":"1","key":"e_1_2_6_9_2","first-page":"S89","article-title":"Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid\u2010dependent patients","volume":"41","author":"McCance\u2010Katz EF.","year":"2005","journal-title":"the importance of drug interactions between opioids and antiretroviral agents"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A447"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.6.547"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000168982.20456.eb"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109070-00015"},{"key":"e_1_2_6_14_2","first-page":"700","article-title":"Use of antiretroviral therapy by intravenous drug users with HIV","volume":"281","author":"Murri R","year":"1999","journal-title":"JAMA"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.6.618"},{"key":"e_1_2_6_16_2","first-page":"660","article-title":"[Commentary] Antiretroviral therapy","volume":"103","author":"Wood E","year":"2008","journal-title":"a key part of the public health response to injection drug use"},{"key":"e_1_2_6_17_2","first-page":"67","article-title":"Deaths in the era of HAART","volume":"20","author":"Sabin CA","year":"2006","journal-title":"contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers"},{"key":"e_1_2_6_18_2","first-page":"378","article-title":"Long\u2010term effectiveness of potent antiretroviral therapy in preventing AIDS and death","volume":"366","author":"Sterne JA","year":"2005","journal-title":"a prospective cohort study"},{"key":"e_1_2_6_19_2","first-page":"412","article-title":"Illicit drug use and HIV\u20101 disease progression","volume":"163","author":"Lucas GM","year":"2006","journal-title":"a longitudinal study in the era of highly active antiretroviral therapy"},{"key":"e_1_2_6_20_2","first-page":"695","article-title":"Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988\u20132000","volume":"158","author":"Galai N","year":"2003","journal-title":"description and determinants"},{"key":"e_1_2_6_21_2","first-page":"863","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV\u20101 patients","volume":"353","author":"Ledergerber B","year":"1999","journal-title":"a prospective cohort study. Swiss HIV Cohort Study"},{"key":"e_1_2_6_22_2","first-page":"385","article-title":"Correlates of self\u2010reported nonadherence to antiretroviral therapy in HIV\u2010infected patients","volume":"41","author":"Glass TR","year":"2006","journal-title":"the Swiss HIV Cohort Study"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/135965350801300108","article-title":"Self\u2010reported non\u2010adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients","volume":"13","author":"Glass TR","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6765.1362"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4049\/jimmunol.146.1.81","article-title":"Cocaine potentiates HIV\u20101 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor\u2010beta","volume":"146","author":"Peterson PK","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.7.1.96-100.2000"},{"key":"e_1_2_6_27_2","first-page":"1027","article-title":"The role of substance abuse in HIV disease progression","volume":"41","author":"Kapadia F","year":"2005","journal-title":"reconciling differences from laboratory and epidemiologic investigations"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(97)00230-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(00)00051-5"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5925-8_18"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200210012-00008"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02135.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/519385"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00006"},{"key":"e_1_2_6_35_2","unstructured":"FOPH.Swiss Federal Office for Public Health: Federal measures to reduce the problems of drug abuse.FOPH basic document 341f Bern 1991."},{"key":"e_1_2_6_36_2","first-page":"1417","article-title":"Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts","volume":"358","author":"Rehm J","year":"2001","journal-title":"a follow-up study"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200401010-00006"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00012"},{"key":"e_1_2_6_39_2","first-page":"1933","article-title":"Poverty and prognosis of HIV infection in Switzerland. Swiss HIV Cohort Study","volume":"12","author":"Ledergerber B","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.25.1.74"},{"key":"e_1_2_6_41_2","first-page":"1466","article-title":"Mortality, CD4 cell count decline, and depressive symptoms among HIV\u2010seropositive women","volume":"285","author":"Ickovics JR","year":"2001","journal-title":"longitudinal analysis from the HIV Epidemiology Research Study"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000103"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00445.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000206508.32030.92"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.11.1214"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f3915e"},{"issue":"5","key":"e_1_2_6_47_2","first-page":"S409","article-title":"Directly administered antiretroviral therapy in an urban methadone maintenance clinic","volume":"38","author":"Lucas GM","year":"2004","journal-title":"a nonrandomized comparative study"},{"key":"e_1_2_6_48_2","first-page":"188","article-title":"Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co\u2010infected injection drug users","volume":"84","author":"Palepu A","year":"2006","journal-title":"the role of methadone maintenance therapy"},{"key":"e_1_2_6_49_2","first-page":"770","article-title":"Superiority of directly administered antiretroviral therapy over self\u2010administered therapy among HIV\u2010infected drug users","volume":"45","author":"Altice FL","year":"2007","journal-title":"a prospective, randomized, controlled trial"},{"key":"e_1_2_6_50_2","first-page":"2210","article-title":"CD4 cell recovery during successful antiretroviral therapy in na\u00efve HIV\u2010infected patients","volume":"18","author":"Dronda F","year":"2004","journal-title":"the role of intravenous drug use"},{"key":"e_1_2_6_51_2","first-page":"1800","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV\u20101 and hepatitis C virus coinfection","volume":"356","author":"Greub G","year":"2000","journal-title":"the Swiss HIV Cohort Study"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f3cc21"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826088109039193"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.08.002"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14307-3"},{"key":"e_1_2_6_56_2","first-page":"1689","article-title":"Drug dependence, a chronic medical illness","volume":"284","author":"McLellan AT","year":"2000","journal-title":"implications for treatment, insurance, and outcomes evaluation"},{"key":"e_1_2_6_57_2","first-page":"433","article-title":"Highly active antiretroviral therapy (HAART) among HIV\u2010infected drug users","volume":"101","author":"Smit C","year":"2006","journal-title":"a prospective cohort study of sexual risk and injecting behaviour"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00701.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00701.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:51:32Z","timestamp":1696866692000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00701.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00701.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00701.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}